Exosomal LINC00900 deriving from mesenchymal stem cells inhibits cell growth in thyroid cancer via suppression of PTBP1.
An C., Zhang M., Wang Y., Li Y., Zhang Q., Ji C.
Prospective Study, published in J Mol Histol (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- J Mol Histol (2026)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41491363
- DOI
- 10.1007/s10735-025-10679-x
Abstract (original English)
Exosomes derived from mesenchymal stem cells (MSC-exo) have the potential to regulate cancer progression by delivering various molecules, including long noncoding RNAs (lncRNAs). This study aimed to investigate the functional role and underlying mechanism of exosomal LINC00900, derived from human adipose-derived mesenchymal stem cells (MSCs), in thyroid cancer (TC). MSC-exo was isolated from conditioned medium using differential ultracentrifugation, observed under transmission electron microscopy, and identified through western blotting and an uptake assay. Cell viability, apoptosis, cell cycle progression, and invasion were evaluated by cell counting kit-8 (CCK-8) assay, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, flow cytometry, and transwell invasion assay, respectively. RNA-pull down and RNA immunoprecipitation assays were conducted to evaluate the interaction between LINC00900 and polypyrimidine tract binding protein 1 (PTBP1). A mouse model with subcutaneous xenografts of the TC cell line TPC-1 was used to assess tumor growth in vivo. The isolated MSC-exo exhibited classic exosome characteristics and could effectively be delivered to TPC-1 cells. MSC-exo significantly inhibited the proliferation of TPC-1 cells and promoted their apoptosis, as evidenced by a decreased optical density value and an increased percentage of apoptotic cells. Foll
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.